13F Holdings
中文EN

EYPT EyePoint, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1314102 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.9%
TTM net income YoY-66.5%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR-60.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-13,642.0%
Net margin-13,281.2%
FCF margin-11,599.4%
EBITDA margin-13,533.9%

Returns

ROE-221.9%
ROA-164.0%
ROIC (approx.)-368.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets34.7%
Debt / equity0.00x
Current ratio3.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue170.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$31.37M$43.27M$46.02M$41.40M$36.94M
R&D expense$221.04M$132.93M$64.66M$49.64M$28.50M
SG&A expense$51.61M$52.36M$40.10M$34.82M$25.57M
Operating income-$243.43M-$145.85M-$75.07M-$99.64M-$55.28M
Interest expense$33,000$14,000$1.25M$3.19M$5.50M
Pretax income-$231.68M-$130.78M-$70.71M-$102.25M-$58.42M
Income tax$279,000$90,000$83,000$0$0
Net income-$231.96M-$130.87M-$70.80M-$102.25M-$58.42M
EBITDA-$241.12M-$144.31M-$74.60M-$99.24M-$54.97M
EPS (basic)-3.17-2.32-1.82-2.74-2.03
EPS (diluted)-3.17-2.32-1.82-2.74-2.03
Weighted avg. shares (diluted)73,25156,29838,90437.32M28.76M
Balance sheet
Cash & equivalents$101.82M$99.85M$281.41M$95.78M$178.74M
Short-term investments$204.26M$271.21M$49.79M$48.93M$32.97M
Inventory$1.81M$2.31M$3.91M$2.89M$3.62M
Current assets$328.65M$383.31M$344.80M$172.81M$237.75M
PP&E, net$9.02M$8.18M$5.25M$1.36M$476,000
Intangibles———$0$22.75M
Total assets$364.00M$418.46M$355.18M$180.36M$263.37M
Current liabilities$37.02M$49.05M$63.26M$34.54M$23.66M
Short-term debt——$0$10.47M$0
Long-term debt———$29.31M$36.56M
Total debt———$39.78M$36.56M
Total liabilities$57.88M$81.96M$88.86M$83.99M$78.99M
Shareholders' equity$306.11M$336.50M$266.32M$96.37M$184.38M
Net debt———-$56.00M-$142.18M
Shares outstanding82.83M68.27M49.04M34.08M33.91M
Cash flow statement
Operating cash flow-$240.11M-$126.23M$1.88M-$65.00M-$50.10M
Capital expenditure$3.28M$4.05M$3.48M$2.15M$156,000
Free cash flow-$243.39M-$130.28M-$1.61M-$67.16M-$50.25M
Investing cash flow$68.58M-$219.35M-$3.31M-$17.27M-$33.12M
Financing cash flow$173.65M$164.02M$187.07M-$690,000$216.90M
Depreciation & amortization$2.31M$1.54M$464,000$396,000$311,000
Stock-based compensation$27.87M$36.74M$12.06M$14.18M$7.45M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.